1863
The risk of developing sAML is estimated to be between 1% and 5%, 2-20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents.
 sAML: Effect; 2-20 years after exposure to etoposide: Treatment; etoposide: Treatment.Drug; 2-20 years: Treatment.Time_elapsed
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 sAML: Effect; 2-20 years after exposure to etoposide: Treatment; etoposide: Treatment.Drug; 2-20 years: Treatment.Time_elapsed